|
Avaliação DCF da Chimerix, Inc. (CMRX)
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Chimerix, Inc. (CMRX) Bundle
Avalie as perspectivas financeiras da Chimerix, Inc. (CMRX) como um especialista! Esta calculadora DCF (CMRX) apresenta finanças pré-preenchidas e oferece total flexibilidade para modificar o crescimento da receita, WACC, margens e outras suposições essenciais para se alinhar às suas projeções.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.5 | 5.4 | 2.0 | 33.8 | .3 | .2 | .2 | .1 | .1 | .1 |
| Revenue Growth, % | 0 | -57.09 | -63.16 | 1609.15 | -99.04 | -29.82 | -29.82 | -29.82 | -29.82 | -29.82 |
| EBITDA | -44.7 | -44.1 | -90.3 | -60.4 | -93.0 | -.2 | -.2 | -.1 | -.1 | -.1 |
| EBITDA, % | -356.8 | -821.18 | -4565.08 | -178.53 | -28695.68 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | .5 | .4 | .5 | .1 | .1 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 3.9 | 7.22 | 23.65 | 0.31634 | 28.09 | 12.63 | 12.63 | 12.63 | 12.63 | 12.63 |
| EBIT | -45.2 | -44.5 | -90.8 | -60.5 | -93.1 | -.2 | -.2 | -.1 | -.1 | -.1 |
| EBIT, % | -360.7 | -828.41 | -4588.73 | -178.85 | -28723.77 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 113.5 | 79.0 | 88.4 | 217.3 | 182.8 | .2 | .2 | .1 | .1 | .1 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .1 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 1.2 | .3 | .3 | 1.0 | 1.1 | .1 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 9.85 | 6.33 | 17.58 | 3.07 | 351.85 | 27.37 | 27.37 | 27.37 | 27.37 | 27.37 |
| Inventories | .0 | .0 | 2.8 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 0 | 0 | 139.46 | 0 | 0 | 20 | 20 | 20 | 20 | 20 |
| Accounts Payable | 2.4 | 1.3 | 2.8 | 3.0 | 2.9 | .1 | .1 | .1 | .0 | .0 |
| Accounts Payable, % | 19.15 | 23.88 | 140.88 | 8.97 | 879.94 | 50.4 | 50.4 | 50.4 | 50.4 | 50.4 |
| Capital Expenditure | -.2 | -.1 | -.2 | -.1 | -.1 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | -1.26 | -1.08 | -10.46 | -0.20991 | -27.47 | -8.1 | -8.1 | -8.1 | -8.1 | -8.1 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -69.7 | -43.1 | -134.1 | -60.5 | -93.1 | -.2 | -.2 | -.1 | -.1 | -.1 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -68.2 | -43.0 | -135.1 | -58.1 | -93.3 | -1.9 | -.2 | -.1 | -.1 | -.1 |
| WACC, % | 5.65 | 5.65 | 5.65 | 5.65 | 5.65 | 5.65 | 5.65 | 5.65 | 5.65 | 5.65 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -2.1 | |||||||||
| Long Term Growth Rate, % | 0.50 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | -1 | |||||||||
| Present Terminal Value | -1 | |||||||||
| Enterprise Value | -3 | |||||||||
| Net Debt | -26 | |||||||||
| Equity Value | 23 | |||||||||
| Diluted Shares Outstanding, MM | 89 | |||||||||
| Equity Value Per Share | 0.26 |
What You Will Gain
- Pre-Filled Financial Model: Chimerix, Inc.'s (CMRX) actual data provides accurate DCF valuation.
- Comprehensive Forecast Control: Modify revenue growth, profit margins, WACC, and other essential factors.
- Real-Time Calculations: Automatic updates allow you to view results instantly as you make adjustments.
- Professional-Grade Template: A polished Excel file crafted for high-quality valuation.
- Flexible and Reusable: Designed for adaptability, enabling repeated use for in-depth forecasts.
Key Features
- Comprehensive CMRX Data: Pre-filled with Chimerix’s historical financials and future projections.
- Fully Customizable Inputs: Modify revenue growth, profit margins, discount rates, tax implications, and capital investments.
- Dynamic Valuation Model: Automatic recalculations of Net Present Value (NPV) and intrinsic value based on your adjustments.
- Scenario Testing: Develop various forecast scenarios to evaluate different valuation results.
- User-Friendly Design: Intuitive, organized, and tailored for both professionals and newcomers.
How It Works
- Step 1: Download the prebuilt Excel template featuring Chimerix, Inc. (CMRX) data.
- Step 2: Navigate through the filled sheets to familiarize yourself with the essential metrics.
- Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Instantly see the updated results, including Chimerix, Inc.'s (CMRX) intrinsic value.
- Step 5: Use the outputs to make informed investment decisions or create detailed reports.
Why Choose This Calculator for Chimerix, Inc. (CMRX)?
- Designed for Experts: A specialized tool utilized by investors, analysts, and financial advisors.
- Accurate Data: Chimerix's historical and projected financials preloaded for precision.
- Flexible Scenario Analysis: Easily simulate various forecasts and assumptions.
- Comprehensive Outputs: Automatically computes intrinsic value, NPV, and essential metrics.
- User-Friendly: Step-by-step guidance to help you navigate the calculator effortlessly.
Who Should Use This Product?
- Investors: Assess Chimerix, Inc.'s (CMRX) valuation before making investment decisions.
- CFOs and Financial Analysts: Optimize valuation methodologies and evaluate financial forecasts.
- Startup Founders: Understand the valuation strategies of established biotech firms like Chimerix, Inc.
- Consultants: Provide detailed valuation analyses and reports for clients in the healthcare sector.
- Students and Educators: Utilize current data to learn and teach valuation principles effectively.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Chimerix, Inc. (CMRX) historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Chimerix, Inc. (CMRX).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.